Ardelyx (ARDX)
NASDAQ:ARDX
Top Page
Ardelyx
(NASDAQ:ARDX)
Select Model
Select Model
Rating:49Neutral
Price Target:
$6.50
▲(5.18% Upside)
Action:ReiteratedDate:02/20/26
The score is weighed down primarily by weak financial quality—ongoing losses, negative free cash flow, and higher leverage—despite strong revenue growth and high gross margins. Technical signals are also soft (below the 20-day average with negative MACD). Offsetting these are constructive earnings call takeaways, including strong 2026 revenue guidance, improved cash dynamics, and pipeline/IP progress, but higher planned spending and XPHOZAH reimbursement headwinds temper the outlook.
Positive Factors
Rapid Revenue Growth (IBSRELA)
IBSRELA's rapid revenue acceleration and raised 2026 guidance indicate durable product-market fit and expanding prescriber adoption. Sustained, predictable unit volume should create a recurring, scalable revenue base to fund commercialization and pipeline work, improving long-term cash generation if execution holds.
Negative Factors
Negative Cash Generation
Persistent negative operating and free cash flow (approx. −$42M and −$44M in 2025) shows the business has not achieved self-funding. Continued cash burn increases reliance on external capital, raising dilution or refinancing risk and limiting flexibility for larger strategic investments or sustained R&D spending.
Read all positive and negative factors
Positive Factors
Negative Factors
Rapid Revenue Growth (IBSRELA)
IBSRELA's rapid revenue acceleration and raised 2026 guidance indicate durable product-market fit and expanding prescriber adoption. Sustained, predictable unit volume should create a recurring, scalable revenue base to fund commercialization and pipeline work, improving long-term cash generation if execution holds.
Read all positive factors
Ardelyx (ARDX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.52B
Dividend YieldN/A
Average Volume (3M)3.12M
Price to Earnings (P/E)―
Beta (1Y)0.79
Revenue Growth58.12%
EPS Growth24.08%
CountryUS
Employees395
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.00
Shares Outstanding245,247,420
10 Day Avg. Volume2,939,253
30 Day Avg. Volume3,124,593
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)8.42
Price to Sales (P/S)3.45
P/FCF Ratio-31.96
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue4.16
Enterprise Value/Gross Profit4.61
Enterprise Value/Ebitda-58.14
Forecast
1Y Price Target
$16.33Price Target Upside164.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.02
Revenue Forecast (FY)$550.07M
Ardelyx Business Overview & Revenue Model
Company Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, ...
How the Company Makes Money
Ardelyx generates revenue primarily through the commercialization of its pharmaceutical products, including tenapanor, which is marketed for specific indications. The company earns money through direct sales to healthcare providers and pharmacies....
Ardelyx Earnings Call Summary
Earnings Call Date:Feb 19, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Positive
The call emphasized strong commercial momentum driven by IBSRELA (73% revenue growth in 2025), meaningful revenue guidance and a strengthened pipeline (Phase III CIC trial and next-gen NHE3), supported by improved cash and a new Orange Book-listed formulation patent. Counterbalancing that are a sizable decline in XPHOZAH revenue due to Medicare reimbursement changes, materially higher SG&A/R&D spending and a wider net loss. Management is investing to scale IBSRELA and advance pipeline programs and expects these investments to drive outsized revenue growth versus expense growth over time.Positive Updates
IBSRELA Strong Revenue Growth
IBSRELA net revenue of $274.2M in 2025, up 73% vs 2024; Q4 year-over-year growth of 61%. Company expects IBSRELA 2026 revenue of $410M–$430M (at least +50% YoY at the low end) and projects $1B in revenue by 2029 (CAGR ~38%).
Negative Updates
XPHOZAH Revenue Decline Driven by Medicare Part D Change
XPHOZAH revenue fell to $103.6M in 2025 from $160.9M in 2024, a decline of 36% year-over-year, largely due to loss of Part D reimbursement for Medicare patients as of Jan 1, 2025 (Medicare represented ~60% of the XPHOZAH patient base).
Read all updates
Q4-2025 Updates
Positive
Negative
IBSRELA Strong Revenue Growth
IBSRELA net revenue of $274.2M in 2025, up 73% vs 2024; Q4 year-over-year growth of 61%. Company expects IBSRELA 2026 revenue of $410M–$430M (at least +50% YoY at the low end) and projects $1B in revenue by 2029 (CAGR ~38%).
Read all positive updates
Company Guidance
Ardelyx guided 2026 IBSRELA revenue of $410–$430 million (at least 50% YoY growth at the low end) and XPHOZAH revenue of $110–$120 million, reaffirming a longer‑term IBSRELA target of $1.0 billion in 2029 (implying a 38% CAGR) and an XPHOZAH peak opportunity of $750 million prior to the 2034 patent expiry. They expect 2026 Q1 phasing to resemble 2025 (≈16% of full‑year IBSRELA revenue), gross‑to‑net deductions to be similar to 2025, and plan ~25% higher 2026 operating expenses (OpEx up to ~$520 million) to fund increased R&D and SG&A. For context, full‑year 2025 results were $407.3 million total revenue (+22% YoY) with IBSRELA $274.2M (+73% YoY) and XPHOZAH $103.6M (−36%), R&D $71.5M, SG&A $337.2M, net loss $61.6M ($0.26/sh), $49M in share‑based comp, cash of $264.7M and two consecutive quarters of positive cash flow. Pipeline and timing: the ACCEL Phase III CIC study plans ~700 patients across ~110 U.S. sites with topline in H2 2027 (sNDA to follow), and an IND for next‑gen NHE3 candidate 531 is targeted in H2 2026 with a Phase I to follow.Ardelyx Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
47
Neutral
Cash Flow
38
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 407.32M | 333.62M | 124.46M | 52.16M | 10.10M |
| Gross Profit | 367.78M | 283.06M | 106.66M | 48.04M | 9.10M |
| EBITDA | -29.17M | -16.71M | -55.35M | -60.98M | -150.85M |
| Net Income | -61.60M | -39.14M | -66.07M | -67.21M | -158.16M |
Balance Sheet | |||||
| Total Assets | 501.60M | 435.75M | 297.58M | 190.07M | 149.91M |
| Cash, Cash Equivalents and Short-Term Investments | 264.69M | 250.10M | 184.30M | 123.91M | 116.69M |
| Total Debt | 211.59M | 153.44M | 55.98M | 36.46M | 45.50M |
| Total Liabilities | 334.65M | 262.46M | 130.76M | 91.74M | 67.30M |
| Stockholders Equity | 166.95M | 173.29M | 166.82M | 98.33M | 82.62M |
Cash Flow | |||||
| Free Cash Flow | -43.98M | -45.82M | -90.06M | -70.10M | -154.42M |
| Operating Cash Flow | -42.48M | -44.81M | -89.72M | -70.04M | -152.55M |
| Investing Cash Flow | -8.96M | -18.32M | -131.25M | 18.41M | 50.95M |
| Financing Cash Flow | 54.51M | 106.59M | 146.29M | 75.34M | 83.00M |
Ardelyx Technical Analysis
Positive
6.18
Price Trends
6.35
Negative
6.32
Negative
5.82
Positive
Market Momentum
-0.03
Negative
55.45
Neutral
88.03
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARDX, the sentiment is Positive. The current price of 6.18 is above the 20-day moving average (MA) of 5.76, below the 50-day MA of 6.35, and above the 200-day MA of 5.82, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 55.45 is Neutral, neither overbought nor oversold. The STOCH value of 88.03 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ARDX.
Ardelyx Risk Analysis
Ardelyx disclosed 52 risk factors in its most recent earnings report. Ardelyx reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ardelyx Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $1.72B | 110.29 | 5.17% | ― | 14.05% | 241.86% | |
66 Neutral | $4.75B | -9.59 | ― | ― | -42.64% | -39.78% | |
61 Neutral | $3.52B | -12.72 | -31.97% | ― | ― | -5.73% | |
57 Neutral | $1.71B | ― | -70.76% | ― | ― | -20.08% | |
54 Neutral | $1.53B | -5.48 | -58.44% | ― | 23340.07% | 18.06% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.52B | -22.81 | -40.63% | ― | 58.12% | 24.08% |
* Healthcare Sector Average
ARDX
Ardelyx
6.18
1.61
35.23%
VCEL
Vericel
33.70
-7.53
-18.26%
VRDN
Viridian Therapeutics
14.95
1.65
12.41%
DNTH
Dianthus Therapeutics
89.77
71.06
379.80%
PHVS
Pharvaris
26.63
14.01
111.01%
EWTX
Edgewise Therapeutics
32.82
20.49
166.18%
Ardelyx Corporate Events
Business Operations and StrategyFinancial Disclosures
Ardelyx Posts Strong 2025 Results, Projects 2026 Growth
Positive
Feb 19, 2026
On February 19, 2026, Ardelyx reported its fourth-quarter and full-year 2025 results, highlighting a 73% surge in IBSRELA revenue to $274.2 million and total revenue of $407.3 million, alongside $103.6 million from XPHOZAH. Despite higher RD and S...
Regulatory Filings and Compliance
Ardelyx files procedural regulatory disclosure update notice
Neutral
Jan 8, 2026
Ardelyx issued a brief regulatory filing note stating that information previously provided under Item 2.02 has been formally incorporated by reference into Item 8.01. The disclosure is purely procedural and does not provide new operational, financ...
Executive/Board Changes
Ardelyx Announces Key Leadership Transitions
Neutral
Dec 17, 2025
Ardelyx, Inc., a company operating in the pharmaceutical or healthcare sector, announced leadership transitions involving two key executives. On December 17, 2025, Elizabeth Grammer, Chief Legal and Administrative Officer, informed the company of ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.